Differences in treatment for advanced ovarian cancer could explain why UK survival lags behind other countries

October 4, 2012
Differences in treatment for advanced ovarian cancer could explain why UK survival lags behind other countries

The main reason women are less likely to survive ovarian cancer in the UK than in other comparable countries appears to be due to very low survival in those with more advanced stages of the disease, shows new research published in the journal Gynecologic Oncology.

This research is part of the International Cancer Benchmarking Partnership (ICBP) - a unique global collaboration funded by the Department of Health.

Overall, the UK had similar proportions of diagnosed at each stage of the disease as in the other participating countries (Australia, Canada, Denmark and Norway). This indicates that differences in access to treatment, or in the quality of care, could play the largest role in the UK's lower survival for , along with other factors such as having another illness which may prevent some women from receiving or completing a specific treatment.

Researchers from Cancer Research UK's Group at the London School of Hygiene and Tropical Medicine examined the records of 20,073 women diagnosed with ovarian cancer between 2004 and 2007 to see how many survived for at least one year, and how this compared with the other four countries.

They found that in the UK, 69 per cent survived for at least a year compared to 72 per cent in Denmark and 74-75 per cent in Australia, Canada and Norway.

Survival in the UK was lower among women whose ovarian cancer was diagnosed at a late stage, and for those whose disease stage had not been recorded. This difference for late-stage cancer was greatest for women diagnosed at age 70 years or more, among whom just 35 per cent survived for at least a year, compared to 45 per cent in Canada.

The UK was also much worse at actually recording the stage at diagnosis.

Dr Bernard Rachet, lead author from the Cancer Survival Group at the London School of Hygiene and Tropical Medicine, said: "Our research is the first population-based study to examine whether low ovarian cancer survival in the UK is due to more women being diagnosed with advanced disease, or to the outcome of treatment in the UK being inferior at each stage. The results show that the proportion of women with advanced disease is similar to that in other countries, but that survival for women with advanced disease is much lower. This suggests that the success of treatment is lower in the UK, and more effort should be made to ensure that UK women with ovarian cancer have the same access to the best treatments."

Dr John Butler, study author and Cancer Research UK clinical advisor for the ICBP project from the Royal Marsden Hospital, said: "Ovarian cancer can be very difficult to treat, because it's not just one disease but several different diseases, depending on the type of the tumour. The most common form, high grade serous ovarian cancer, is thought to develop in the fallopian tube, rather than the ovary, and it often spreads rapidly before a woman notices any symptoms. This is why many ovarian cancers are not detected until they are more advanced. But in order for us to understand why we have lower ovarian cancer survival and how we can focus on improving treatment for later stage disease, the UK must get better at recording the stage of disease at diagnosis."

Sara Hiom, director of information at Cancer Research UK, said: "This disturbing research advances our knowledge about what needs to be done to tackle lower ovarian cancer survival in the UK. The results show that achieving earlier diagnosis remains vital for improving overall survival. If women are diagnosed when the cancer is still in its early stages, before it has spread to other parts of the body, it is far more likely that treatment will be successful. In addition treatment must be improved for advanced stage cancers."

Explore further: Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

More information: Maringe et al. Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology. doi: 10.1016/j.ygyno.2012.06.033

Related Stories

Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

December 20, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that the commonest type of ovarian cancer evolves at a startling rate, which may allow cancer cells to ‘dodge’ the current standard treatment, reveals ...

Targeted testing offers treatment hope for ovarian cancer patients

May 31, 2011
Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

Age affects risk of being diagnosed with cancer at advanced stage

March 2, 2012
Older women with breast cancer face a higher risk of being diagnosed with the disease at a late stage, while the risk of an advanced stage diagnosis of lung cancer decreases with age, a new study shows today.

Gene helps predict which ovarian cancer sufferers will benefit most from chemotherapy

September 19, 2012
(Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy drugs - a common ...

Pill and pregnancy have biggest effects on ovarian cancer risk

October 26, 2011
(Medical Xpress) -- Taking the Pill for 10 years can reduce the risk of ovarian cancer by almost half (45 per cent), new research part-funded by Cancer Research UK shows today.

Recommended for you

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.